open access

Vol 90, No 3 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-03-29
Get Citation

The potential predictive value of serum sRCAS1 levels for overall survival in endometrial cancer

Sebastian Szubert, Krzysztof Koper, Magdalena Maria Dutsch-Wicherek, Zbigniew Kojs
DOI: 10.5603/GP.2019.0024
·
Pubmed: 30950002
·
Ginekol Pol 2019;90(3):134-140.

open access

Vol 90, No 3 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-03-29

Abstract

Objectives: The main aim of the study was to evaluate the impact of levels of serum soluble receptor-binding cancer antigen expressed on SiSo cells (sRCAS1) on the overall survival (OS) rates in patients with endometrial cancer. Furthermore, we analyzed sRCAS1 levels according to the clinicopathological characteristics of the disease.  Material and methods: The study group comprised 43 patients who were being treated for endometrial cancer. We included 10 low-risk, 20 intermediate-risk and 13 high-risk endometrial cancers using the criteria of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Gynaecological Oncology (ESGO). Serum sRCAS1 levels were obtained before and after surgery. Serum sRCAS1 levels were assessed using the ELISA method.  Results: In our univariate analysis, both the pre- and post-surgery high sRCAS1 groups of patients with endometrial cancer indicated a shortened OS. However, in our multivariate analysis, when patients’ age and disease-related risk was taken into consideration, only the post-surgery sRCAS1 levels remained as independent prognostic factors of a poor OS. Pre-treatment serum sRCAS1 levels were statistically significantly higher than post-surgery sRCAS1 levels; however, the difference between pre- and post-surgery sRCAS1 levels did not influence the patients’ OS rate. Pre- and post-surgery sRCAS1 levels did not differ according to tumor grade, stage of the disease or the disease-related risk group.  Conclusions: High post-surgery serum sRCAS1 levels seem to be an independent indicator of shortened overall survival in patients with endometrial cancer. 

Abstract

Objectives: The main aim of the study was to evaluate the impact of levels of serum soluble receptor-binding cancer antigen expressed on SiSo cells (sRCAS1) on the overall survival (OS) rates in patients with endometrial cancer. Furthermore, we analyzed sRCAS1 levels according to the clinicopathological characteristics of the disease.  Material and methods: The study group comprised 43 patients who were being treated for endometrial cancer. We included 10 low-risk, 20 intermediate-risk and 13 high-risk endometrial cancers using the criteria of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Gynaecological Oncology (ESGO). Serum sRCAS1 levels were obtained before and after surgery. Serum sRCAS1 levels were assessed using the ELISA method.  Results: In our univariate analysis, both the pre- and post-surgery high sRCAS1 groups of patients with endometrial cancer indicated a shortened OS. However, in our multivariate analysis, when patients’ age and disease-related risk was taken into consideration, only the post-surgery sRCAS1 levels remained as independent prognostic factors of a poor OS. Pre-treatment serum sRCAS1 levels were statistically significantly higher than post-surgery sRCAS1 levels; however, the difference between pre- and post-surgery sRCAS1 levels did not influence the patients’ OS rate. Pre- and post-surgery sRCAS1 levels did not differ according to tumor grade, stage of the disease or the disease-related risk group.  Conclusions: High post-surgery serum sRCAS1 levels seem to be an independent indicator of shortened overall survival in patients with endometrial cancer. 

Get Citation

Keywords

sRCAS1; RCAS1; receptor-binding cancer antigen expressed on SiSo cells; endometrial cancer; cancer immunology

About this article
Title

The potential predictive value of serum sRCAS1 levels for overall survival in endometrial cancer

Journal

Ginekologia Polska

Issue

Vol 90, No 3 (2019)

Pages

134-140

Published online

2019-03-29

DOI

10.5603/GP.2019.0024

Pubmed

30950002

Bibliographic record

Ginekol Pol 2019;90(3):134-140.

Keywords

sRCAS1
RCAS1
receptor-binding cancer antigen expressed on SiSo cells
endometrial cancer
cancer immunology

Authors

Sebastian Szubert
Krzysztof Koper
Magdalena Maria Dutsch-Wicherek
Zbigniew Kojs

References (35)
  1. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016; 387(10023): 1094–1108.
  2. Walentowicz-Sadlecka M, Dziobek K, Grabiec M, et al. The analysis of human leukocyte antigen-G level in patients with endometrial cancer by Western blot technique. Am J Reprod Immunol. 2019; 81(1): e13070.
  3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6): 403–409.
  4. Wei J, Zhang W, Feng L, et al. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review. Medicine (Baltimore). 2017; 96(37): e8034.
  5. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104(21): 1625–1634.
  6. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
  7. Bosse T, Nout RA, Stelloo E, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer. 2014; 50(15): 2602–2610.
  8. Tsuchiya F, Ikeda K, Tsutsumi O, et al. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem Biophys Res Commun. 2001; 284(1): 2–10.
  9. Galazka K, Opławski M, Windorbska W, et al. The immunohistochemical analysis of antigens such as RCAS1 and B7H4 in the cervical cancer nest and within the fibroblasts and macrophages infiltrating the cancer microenvironment. Am J Reprod Immunol. 2012; 68(1): 85–93.
  10. Nishinakagawa T, Fujii S, Nozaki T, et al. Analysis of cell cycle arrest and apoptosis induced by RCAS1. Int J Mol Med. 2010; 25(5): 717–722.
  11. Biedka M, Nowikiewicz T, Dziobek K, et al. The analysis of Treg lymphocytes in the blood of patients with breast cancer during the combined oncological treatment. Breast J. 2019; 26(1).
  12. Wicherek L. The role of the endometrium in the regulation of immune cell activity. Front Biosci. 2008; 13: 1018–1035.
  13. Sonoda K, Miyamoto S, Nakashima M, et al. The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci. 2008; 13: 1106–1116.
  14. Dutsch-Wicherek M, Wicherek L. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol. 2008; 59(3): 266–275.
  15. Dutsch-Wicherek M, Tomaszewska R, Lazar A, et al. The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer. 2009; 9: 35.
  16. Sonoda K, Miyamoto S, Hirakawa T, et al. Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol. 2005; 99(1): 189–198.
  17. Popiela TJ, Rudnicka-Sosin L, Dutsch-Wicherek M, et al. The metallothionein and RCAS1 expression analysis in breast cancer and adjacent tissue regarding the immune cells presence and their activity. Neuro Endocrinol Lett. 2006; 27(6): 786–794.
  18. Wicherek L, Dutsch-Wicherek M, Galazka K, et al. Comparison of RCAS1 and metallothionein expression and the presence and activity of immune cells in human ovarian and abdominal wall endometriomas. Reprod Biol Endocrinol. 2006; 4: 41.
  19. Sonoda K, Miyamoto S, Yamazaki A, et al. Biologic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer. 2007; 110(9): 1979–1990.
  20. Szymankiewicz M, Koper K, Dziobek K, et al. Microbiological monitoring in patients with advanced ovarian cancer before and after cytoreductive surgery – a preliminary report. Current Issues in Pharmacy and Medical Sciences. 2017; 30(4): 198–202.
  21. Opławski M, Dziobek K, Adwent I, et al. Expression Profile of Endoglin in Different Grades of Endometrial Cancer. Current Pharmaceutical Biotechnology. 2019; 19(12): 990–995.
  22. Sonoda K, Miyamoto S, Nakashima M, et al. Receptor-binding cancer antigen expressed on SiSo cells induces apoptosis via ectodomain shedding. Exp Cell Res. 2010; 316(11): 1795–1803.
  23. Sonoda K, Miyamoto S, Hirakawa T, et al. Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol. 2006; 103(3): 924–931.
  24. Han Sx, Wang J, Wang Lj, et al. The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis. Tumour Biol. 2014; 35(6): 6149–6157.
  25. Giaginis C, Efkarpidis T, Alexandrou P, et al. Increased RCAS1 expression is associated with advanced histopathological stage and poor prognosis in patients with gastric adenocarcinoma. Dis Markers. 2013; 35(4): 213–219.
  26. Jozwicki W, Windorbska W, Brozyna AA, et al. The analysis of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy. Cell Tissue Res. 2011; 345(3): 405–414.
  27. Wicherek L, Basta P, Wertel I, et al. Analysis of RCAS1 Immunoreactivity within Hydatidiform Mole Cells and Decidual Cells according to the Applied Therapeutic Strategy: Surgery or Surgery Followed by Chemotherapy. Gynecologic and Obstetric Investigation. 2012; 73(2): 106–112.
  28. Szymankiewicz M, Dziobek K, Sznajdorwska M, et al. An analysis of the influence of infection on overall survival rates, following modified posterior pelvic exenteration for advanced ovarian cancer. Ginekol Pol. 2018; 89(11): 618–626.
  29. Enjoji M, Nakashima M, Yamaguchi K, et al. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. J Gastroenterol Hepatol. 2005; 20(8): 1143–1148.
  30. Koper K, Dziobek K, Makarewicz R, et al. The analysis of the long-term outcomes in elderly women treated for locally advanced cervical cancer. J Contemp Brachytherapy. 2018; 10(5): 411–417.
  31. Sonoda K, Miyamoto S, Hirakawa T, et al. Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br J Cancer. 2003; 89(3): 546–551.
  32. Sonoda K, Kaku T, Hirakawa T, et al. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol. 2000; 79(3): 424–429.
  33. Zhou XH, Teng XD, Song WY, et al. Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer. 2008; 18(1): 152–158.
  34. Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006; 103(1): 87–93.
  35. Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, et al. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther. 2013; 9: 1305–1313.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl